Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Vaccines

  Free Subscription


Articles published in PLoS Med

Retrieve available abstracts of 53 articles:
HTML format



Single Articles


    February 2024
  1. NICKEL NC, Phillips-Beck W, Enns JE, Ekuma O, et al
    COVID-19 diagnostic testing and vaccinations among First Nations in Manitoba: A nations-based retrospective cohort study using linked administrative data, 2020-2021.
    PLoS Med. 2024;21:e1004348.
    PubMed     Abstract available


    January 2024
  2. GHARPURE R, Chard AN, Cabrera Escobar M, Zhou W, et al
    Costs and cost-effectiveness of influenza illness and vaccination in low- and middle-income countries: A systematic review from 2012 to 2022.
    PLoS Med. 2024;21:e1004333.
    PubMed     Abstract available


    November 2023
  3. HOGAN AB, Wu SL, Toor J, Olivera Mesa D, et al
    Long-term vaccination strategies to mitigate the impact of SARS-CoV-2 transmission: A modelling study.
    PLoS Med. 2023;20:e1004195.
    PubMed     Abstract available


  4. BRENNHOFER SA, Platts-Mills JA, Lewnard JA, Liu J, et al
    Burden of diarrhea and antibiotic use among children in low-resource settings preventable by Shigella vaccination: A simulation study.
    PLoS Med. 2023;20:e1004271.
    PubMed     Abstract available


    September 2023
  5. WATKINSON RE, Williams R, Gillibrand S, Munford L, et al
    Evaluating socioeconomic inequalities in influenza vaccine uptake during the COVID-19 pandemic: A cohort study in Greater Manchester, England.
    PLoS Med. 2023;20:e1004289.
    PubMed     Abstract available


    July 2023
  6. XIONG X, Lui DTW, Chung MSH, Au ICH, et al
    Incidence of diabetes following COVID-19 vaccination and SARS-CoV-2 infection in Hong Kong: A population-based cohort study.
    PLoS Med. 2023;20:e1004274.
    PubMed     Abstract available


  7. PORTNOY A, Arcand JL, Clark RA, Weerasuriya CK, et al
    The potential impact of novel tuberculosis vaccine introduction on economic growth in low- and middle-income countries: A modeling study.
    PLoS Med. 2023;20:e1004252.
    PubMed     Abstract available


    June 2023
  8. STOWE J, Miller E, Andrews N, Whitaker HJ, et al
    Risk of myocarditis and pericarditis after a COVID-19 mRNA vaccine booster and after COVID-19 in those with and without prior SARS-CoV-2 infection: A self-controlled case series analysis in England.
    PLoS Med. 2023;20:e1004245.
    PubMed     Abstract available


  9. QIN K, Honjo K, Sherrill-Mix S, Liu W, et al
    Exposure of progressive immune dysfunction by SARS-CoV-2 mRNA vaccination in patients with chronic lymphocytic leukemia: A prospective cohort study.
    PLoS Med. 2023;20:e1004157.
    PubMed     Abstract available


    May 2023
  10. KUMAR CK, Sands K, Walsh TR, O'Brien S, et al
    Global, regional, and national estimates of the impact of a maternal Klebsiella pneumoniae vaccine: A Bayesian modeling analysis.
    PLoS Med. 2023;20:e1004239.
    PubMed     Abstract available


    March 2023
  11. MEMIRIE ST, Tolla MT, Rumpler E, Sato R, et al
    Out-of-pocket expenditures and financial risks associated with treatment of vaccine-preventable diseases in Ethiopia: A cross-sectional costing analysis.
    PLoS Med. 2023;20:e1004198.
    PubMed     Abstract available


    February 2023
  12. NORDSTROM P, Ballin M, Nordstrom A
    Safety and effectiveness of monovalent COVID-19 mRNA vaccination and risk factors for hospitalisation caused by the omicron variant in 0.8 million adolescents: A nationwide cohort study in Sweden.
    PLoS Med. 2023;20:e1004127.
    PubMed     Abstract available


    January 2023
  13. DIMITROVA A, Carrasco-Escobar G, Richardson R, Benmarhnia T, et al
    Essential childhood immunization in 43 low- and middle-income countries: Analysis of spatial trends and socioeconomic inequalities in vaccine coverage.
    PLoS Med. 2023;20:e1004166.
    PubMed     Abstract available


  14. WAN J, Cazer CL, Clarkberg ME, Henderson SG, et al
    Booster vaccination protection against SARS-CoV-2 infections in young adults during an Omicron BA.1-predominant period: A retrospective cohort study.
    PLoS Med. 2023;20:e1004153.
    PubMed     Abstract available


  15. HENSLEY KS, Jongkees MJ, Geers D, GeurtsvanKessel CH, et al
    Correction: Immunogenicity and reactogenicity of SARS-CoV-2 vaccines in people living with HIV in the Netherlands: A nationwide prospective cohort study.
    PLoS Med. 2023;20:e1004159.
    PubMed     Abstract available


  16. PORTNOY A, Clark RA, Quaife M, Weerasuriya CK, et al
    The cost and cost-effectiveness of novel tuberculosis vaccines in low- and middle-income countries: A modeling study.
    PLoS Med. 2023;20:e1004155.
    PubMed     Abstract available


  17. BOR J, Assoumou SA, Lane K, Diaz Y, et al
    Inequities in COVID-19 vaccine and booster coverage across Massachusetts ZIP codes after the emergence of Omicron: A population-based cross-sectional study.
    PLoS Med. 2023;20:e1004167.
    PubMed     Abstract available


  18. CERQUEIRA-SILVA T, Shah SA, Robertson C, Sanchez M, et al
    Effectiveness of mRNA boosters after homologous primary series with BNT162b2 or ChAdOx1 against symptomatic infection and severe COVID-19 in Brazil and Scotland: A test-negative design case-control study.
    PLoS Med. 2023;20:e1004156.
    PubMed     Abstract available


    December 2022
  19. LIND ML, Robertson AJ, Silva J, Warner F, et al
    Association between primary or booster COVID-19 mRNA vaccination and Omicron lineage BA.1 SARS-CoV-2 infection in people with a prior SARS-CoV-2 infection: A test-negative case-control analysis.
    PLoS Med. 2022;19:e1004136.
    PubMed     Abstract available


    November 2022
  20. BABOUEE FLURY B, Gusewell S, Egger T, Leal O, et al
    Risk and symptoms of COVID-19 in health professionals according to baseline immune status and booster vaccination during the Delta and Omicron waves in Switzerland-A multicentre cohort study.
    PLoS Med. 2022;19:e1004125.
    PubMed     Abstract available


  21. NIELSEN KF, Moustsen-Helms IR, Schelde AB, Gram MA, et al
    Vaccine effectiveness against SARS-CoV-2 reinfection during periods of Alpha, Delta, or Omicron dominance: A Danish nationwide study.
    PLoS Med. 2022;19:e1004037.
    PubMed     Abstract available


    October 2022
  22. HENSLEY KS, Jongkees MJ, Geers D, GeurtsvanKessel CH, et al
    Immunogenicity and reactogenicity of SARS-CoV-2 vaccines in people living with HIV in the Netherlands: A nationwide prospective cohort study.
    PLoS Med. 2022;19:e1003979.
    PubMed     Abstract available


    September 2022
  23. GRAM MA, Emborg HD, Schelde AB, Friis NU, et al
    Vaccine effectiveness against SARS-CoV-2 infection or COVID-19 hospitalization with the Alpha, Delta, or Omicron SARS-CoV-2 variant: A nationwide Danish cohort study.
    PLoS Med. 2022;19:e1003992.
    PubMed     Abstract available


    August 2022
  24. MODY A, Bradley C, Redkar S, Fox B, et al
    Quantifying inequities in COVID-19 vaccine distribution over time by social vulnerability, race and ethnicity, and location: A population-level analysis in St. Louis and Kansas City, Missouri.
    PLoS Med. 2022;19:e1004048.
    PubMed     Abstract available


    July 2022
  25. HERNANDEZ I, Dickson S, Tang S, Gabriel N, et al
    Disparities in distribution of COVID-19 vaccines across US counties: A geographic information system-based cross-sectional study.
    PLoS Med. 2022;19:e1004069.
    PubMed     Abstract available


  26. MASSARI M, Spila Alegiani S, Morciano C, Spuri M, et al
    Postmarketing active surveillance of myocarditis and pericarditis following vaccination with COVID-19 mRNA vaccines in persons aged 12 to 39 years in Italy: A multi-database, self-controlled case series study.
    PLoS Med. 2022;19:e1004056.
    PubMed     Abstract available


    June 2022
  27. TAKUVA S, Takalani A, Seocharan I, Yende-Zuma N, et al
    Safety evaluation of the single-dose Ad26.COV2.S vaccine among healthcare workers in the Sisonke study in South Africa: A phase 3b implementation trial.
    PLoS Med. 2022;19:e1004024.
    PubMed     Abstract available


  28. WONG CKH, Lau KTK, Xiong X, Au ICH, et al
    Adverse events of special interest and mortality following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines in Hong Kong: A retrospective study.
    PLoS Med. 2022;19:e1004018.
    PubMed     Abstract available


    May 2022
  29. JIN P, Guo X, Chen W, Ma S, et al
    Safety and immunogenicity of heterologous boost immunization with an adenovirus type-5-vectored and protein-subunit-based COVID-19 vaccine (Convidecia/ZF2001): A randomized, observer-blinded, placebo-controlled trial.
    PLoS Med. 2022;19:e1003953.
    PubMed     Abstract available


  30. MARTIN CA, Pan D, Melbourne C, Teece L, et al
    Risk factors associated with SARS-CoV-2 infection in a multiethnic cohort of United Kingdom healthcare workers (UK-REACH): A cross-sectional analysis.
    PLoS Med. 2022;19:e1004015.
    PubMed     Abstract available


  31. PEARSON CAB, Bozzani F, Procter SR, Davies NG, et al
    Correction: COVID-19 vaccination in Sindh Province, Pakistan: A modelling study of health impact and cost-effectiveness.
    PLoS Med. 2022;19:e1003990.
    PubMed     Abstract available


  32. VAN GILS MJ, Lavell A, van der Straten K, Appelman B, et al
    Antibody responses against SARS-CoV-2 variants induced by four different SARS-CoV-2 vaccines in health care workers in the Netherlands: A prospective cohort study.
    PLoS Med. 2022;19:e1003991.
    PubMed     Abstract available


  33. QIAN G, Toizumi M, Clifford S, Le LT, et al
    Association of pneumococcal carriage in infants with the risk of carriage among their contacts in Nha Trang, Vietnam: A nested cross-sectional survey.
    PLoS Med. 2022;19:e1004016.
    PubMed     Abstract available


    April 2022
  34. FOO D, Sarna M, Pereira G, Moore HC, et al
    Prenatal influenza vaccination and allergic and autoimmune diseases in childhood: A longitudinal, population-based linked cohort study.
    PLoS Med. 2022;19:e1003963.
    PubMed     Abstract available


  35. WATKINSON RE, Williams R, Gillibrand S, Sanders C, et al
    Correction: Ethnic inequalities in COVID-19 vaccine uptake and comparison to seasonal influenza vaccine uptake in Greater Manchester, UK: A cohort study.
    PLoS Med. 2022;19:e1003982.
    PubMed     Abstract available


    March 2022
  36. WATKINSON RE, Williams R, Gillibrand S, Sanders C, et al
    Ethnic inequalities in COVID-19 vaccine uptake and comparison to seasonal influenza vaccine uptake in Greater Manchester, UK: A cohort study.
    PLoS Med. 2022;19:e1003932.
    PubMed     Abstract available


    February 2022
  37. SAAKSVUORI L, Betsch C, Nohynek H, Salo H, et al
    Information nudges for influenza vaccination: Evidence from a large-scale cluster-randomized controlled trial in Finland.
    PLoS Med. 2022;19:e1003919.
    PubMed     Abstract available



  38. Vaccine equity: A fundamental imperative in the fight against COVID-19.
    PLoS Med. 2022;19:e1003948.
    PubMed    


  39. KERR S, Joy M, Torabi F, Bedston S, et al
    First dose ChAdOx1 and BNT162b2 COVID-19 vaccinations and cerebral venous sinus thrombosis: A pooled self-controlled case series study of 11.6 million individuals in England, Scotland, and Wales.
    PLoS Med. 2022;19:e1003927.
    PubMed     Abstract available


  40. WHITELEY WN, Ip S, Cooper JA, Bolton T, et al
    Association of COVID-19 vaccines ChAdOx1 and BNT162b2 with major venous, arterial, or thrombocytopenic events: A population-based cohort study of 46 million adults in England.
    PLoS Med. 2022;19:e1003926.
    PubMed     Abstract available


  41. MCQUAID F, Mulholland R, Sangpang Rai Y, Agrawal U, et al
    Uptake of infant and preschool immunisations in Scotland and England during the COVID-19 pandemic: An observational study of routinely collected data.
    PLoS Med. 2022;19:e1003916.
    PubMed     Abstract available


    January 2022
  42. GENTILE I, Schiano Moriello N
    COVID-19 prophylaxis in immunosuppressed patients: Beyond vaccination.
    PLoS Med. 2022;19:e1003917.
    PubMed     Abstract available


  43. ANYWAINE Z, Barry H, Anzala O, Mutua G, et al
    Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in children and adolescents in Africa: A randomised, placebo-controlled, multicentre Phase II clinical trial.
    PLoS Med. 2022;19:e1003865.
    PubMed     Abstract available


    December 2021
  44. GRAM MA, Nielsen J, Schelde AB, Nielsen KF, et al
    Vaccine effectiveness against SARS-CoV-2 infection, hospitalization, and death when combining a first dose ChAdOx1 vaccine with a subsequent mRNA vaccine in Denmark: A nationwide population-based cohort study.
    PLoS Med. 2021;18:e1003874.
    PubMed     Abstract available


  45. PETERSEN M, Schwab J, Havlir DV
    SARS-CoV-2 vaccine boosters: The time to act is now.
    PLoS Med. 2021;18:e1003882.
    PubMed     Abstract available


    November 2021
  46. MARTIN CA, Marshall C, Patel P, Goss C, et al
    SARS-CoV-2 vaccine uptake in a multi-ethnic UK healthcare workforce: A cross-sectional study.
    PLoS Med. 2021;18:e1003823.
    PubMed     Abstract available


  47. BHANU C, Gopal DP, Walters K, Chaudhry UAR, et al
    Vaccination uptake amongst older adults from minority ethnic backgrounds: A systematic review.
    PLoS Med. 2021;18:e1003826.
    PubMed     Abstract available


    October 2021
  48. PEARSON CAB, Bozzani F, Procter SR, Davies NG, et al
    COVID-19 vaccination in Sindh Province, Pakistan: A modelling study of health impact and cost-effectiveness.
    PLoS Med. 2021;18:e1003815.
    PubMed     Abstract available


  49. FORMICA N, Mallory R, Albert G, Robinson M, et al
    Different dose regimens of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373) in younger and older adults: A phase 2 randomized placebo-controlled trial.
    PLoS Med. 2021;18:e1003769.
    PubMed     Abstract available


  50. ISANAKA S, Garba S, Plikaytis B, McNeal MM, et al
    Correction: Immunogenicity of an oral rotavirus vaccine administered with prenatal nutritional support in Niger: A cluster randomized clinical trial.
    PLoS Med. 2021;18:e1003776.
    PubMed     Abstract available


  51. BARRY H, Mutua G, Kibuuka H, Anywaine Z, et al
    Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in healthy and HIV-infected adults: A randomised, placebo-controlled Phase II clinical trial in Africa.
    PLoS Med. 2021;18:e1003813.
    PubMed     Abstract available


  52. GENG EH, Reid MJA, Goosby E, Abdool-Karim Q, et al
    COVID-19 and global equity for health: The good, the bad, and the wicked.
    PLoS Med. 2021;18:e1003797.
    PubMed     Abstract available


    September 2021
  53. NAGATA JM, Epstein A, Ganson KT, Benmarhnia T, et al
    Drought and child vaccination coverage in 22 countries in sub-Saharan Africa: A retrospective analysis of national survey data from 2011 to 2019.
    PLoS Med. 2021;18:e1003678.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Vaccines is free of charge.